Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.
Stock data | 2023 | Change |
---|---|---|
Price | $73.57 | N/A |
Market Cap | $8.80B | N/A |
Shares Outstanding | 119.56M | 0.00% |
Employees | 16.87K | N/A |
Shareholder Equity | 94.35B | 6.64% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 0.89 | N/A |
P/S Ratio | 6.45 | N/A |
P/B Ratio | 0.09 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0013 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.36B | N/A |
Earnings | $120.04M | N/A |
EPS | 82.31 | N/A |
Earnings Yield | 1.12 | N/A |
Gross Margin | 0.5645 | N/A |
Operating Margin | 0.1166 | N/A |
Net income margin | 0.088 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $1.64B | N/A |
Total Debt | $166.52M | N/A |
Cash on Hand | $349.75M | N/A |
Debt to Equity | 0.0055 | -22.39% |
Cash to Debt | $2.10 | 106.20% |
Current Ratio | $2.35 | 34.15% |